Placental GH Inhibitors

Chemical inhibitors of Placental Growth Hormone (GH) can exert their inhibitory effects through various mechanisms that impact the GH signaling pathway. Mecasermin, a recombinant form of human insulin-like growth factor-1, activates the IGF-1 receptor, which can suppress the GH receptor signaling pathway. This suppression is a result of the downstream signaling events that occur upon IGF-1 receptor activation, which in turn can inhibit the activity of Placental GH through a negative feedback loop that usually regulates growth hormone action. Similarly, Pegvisomant acts as a direct antagonist to the growth hormone receptor, binding to it and preventing Placental GH from initiating its typical biological actions, leading to a decrease in GH signaling.

Several somatostatin analogs, such as Octreotide, Lanreotide, and Pasireotide, achieve inhibition of Placental GH indirectly by binding to somatostatin receptors. This binding inhibits adenylate cyclase, subsequently reducing cAMP levels within the cell and suppressing growth hormone release from the pituitary. Although Placental GH is not released by the pituitary, the reduction in overall GH levels can contribute to decreased Placental GH function. Dopamine D2 receptor agonists, including Bromocriptine and Cabergoline, inhibit pituitary secretion of growth hormone, which in turn can inhibit Placental GH activity by reducing the systemic growth hormone signaling. Quinagolide, another dopamine agonist, functions in a similar manner to suppress the secretion of growth hormone from the pituitary gland, which can indirectly inhibit Placental GH activity.

On a cellular level, Temozolomide can inhibit the effects of Placental GH by causing DNA damage in cells that express the GH receptor, impairing the signaling pathways activated by Placental GH. Vorinostat may alter gene expression related to GH receptor signaling by changing the acetylation status of histones, thereby potentially inhibiting Placental GH functionality. Lastly, Bortezomib disrupts the degradation of proteins that regulate GH receptor signaling, which could result in an accumulation of suppressors of the GH receptor signaling pathway, leading to inhibition of the actions typically mediated by Placental GH.